PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 5, 2026Cancer Research0 citations

Abstract 1237: Effects of a home-based walking intervention on serum metabolomic profiles in men with prostate cancer on active surveillance.

View Full Paper
RGRebecca E. GraffRRRitu RoyOFOliver Fiehn

Key Result

A 16-week home-based walking intervention in men with prostate cancer nominally reduced six sphingomyelins (p<0.05) compared to control, without significantly altering overall metabolic profiles.

Key Points

  • This research aims to explore how a home-based walking intervention influences the metabolomic profiles of men with prostate cancer.
  • Randomized allocation of 51 men with prostate cancer to either exercise or control interventions.
  • Metabolomic profiling conducted on serum samples at baseline and after 16 weeks.
  • Data analysis included hierarchical clustering and mixed-effects models to assess metabolic changes.
  • Limited metabolic profile separation was observed between exercise and control groups after 16 weeks.
  • No significant differences in the majority of 1,220 metabolites, but 85 showed nominal significance.
  • Six sphingomyelins decreased more significantly in the exercise group compared to controls, indicating a potential therapeutic effect.

Structured PICO

Does a home-based walking intervention alter serum metabolomic profiles in men with prostate cancer on active surveillance?

P
Population
51 men with prostate cancer on active surveillance
I
Intervention
Home-based walking program for 16 weeks
C
Comparator
Printed materials with physical activity recommendations
O
Outcome
Changes in serum metabolomic profiles (primary metabolism, complex lipids, and biogenic amines) at 16 weekssurrogate

A 16-week home-based walking intervention did not significantly alter overall metabolic profiles in men with prostate cancer on active surveillance, though it may promote the reduction of sphingomyelins.

Abstract

Abstract Introduction: The potential for long-term exercise to affect the metabolome in healthy individuals is well established. Given the metabolic underpinnings of prostate cancer, it is important to investigate whether long-term exercise similarly alters the metabolome in disease-affected men. This study is among the first to characterize metabolic changes in individuals with prostate cancer, comparing those assigned to a home-based walking program to those assigned to printed materials with physical activity recommendations. Methods: Fifty-one men with prostate cancer on active surveillance were randomly allocated to the exercise or control intervention. Metabolomic profiling of primary metabolism, complex lipids, and biogenic amines was performed at the West Coast Metabolomics Center on serum samples collected at baseline and after the 16-week interventions; data were successfully generated for 22 participants in the exercise arm and 23 participants in the control arm. To identify intervention-related differences in metabolic changes, we performed hierarchical clustering and fit mixed-effects models including an arm x time interaction. Results: Hierarchical clustering indicated limited separation in metabolic profiles between the exercise and control groups at 16 weeks. Although none of the 1,220 named metabolites exhibited statistically significant differences in change between the two groups (q0.10), 85 (7.0%) demonstrated nominal significance (p0.05). Among the 15 metabolites with the smallest p-values, six (40%) were sphingolipids - specifically sphingomyelins - though sphingolipids comprised only 11% of all named metabolites. All six sphingomyelins decreased more over time in the exercise group than in the control group. Conclusions: Although metabolic profiles were not significantly altered overall, a walking intervention may promote the reduction of sphingomyelins, thereby shifting lipid signaling toward pathways that enhance mitochondrial function and reduce inflammation. Such changes are consistent with biologically plausible mechanisms through which exercise could favorably influence prostate cancer biology, even in the absence of broad metabolomic shifts. Citation Format: Rebecca E. Graff, Ritu Roy, Oliver Fiehn, Adam Olshen, Erin Van Blarigan, Stacey Kenfield, Jeffry P. Simko, Anthony Luke, Lee Jones, Matthew R. Cooperberg, Peter R. Carroll, June M. Chan. Effects of a home-based walking intervention on serum metabolomic profiles in men with prostate cancer on active surveillance abstract. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 1237.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Graff et al. (2026) studied this question. A 16-week home-based walking intervention in men with prostate cancer nominally reduced six sphingomyelins (p<0.05) compared to control, without significantly altering overall metabolic profiles.

synapsesocial.com/papers/69d1fe18a79560c99a0a495dhttps://doi.org/10.1158/1538-7445.am2026-1237
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Exercise‐Based Interventions for Metabolic and Immune Modulation in Prostate Cancer: A Systematic Review and Meta‐Analysis of RCTs2026
  2. 2A randomized controlled trial of a home-based exercise program on prognostic biomarkers in men with prostate cancer: A study protocol2020 · 1 citations
  3. 3Inflammation and insulin profiles in men assigned to exercise vs. usual care for prostate cancer: results from the active surveillance exercise (ASX) randomized controlled trial2026
  4. 4Abstract CT232: Intense exercise for survival among men with metastatic prostate cancer: 12-month feasibility results from the INTERVAL-GAP4 trial pilot site at Edith Cowan University, Australia2024
  5. 5Abstract 3627: Metabolomic signatures of physical activity in treatment-naive patients with early-onset vs. late-onset colorectal cancer: Results from the ColoCare Study2026